Advertisement

Anticoagulation Monitoring for Percutaneous Transluminal Coronary Angioplasty

  • James J. Ferguson
  • James M. Wilson
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 193)

Abstract

Percutaneous transluminal coronary angioplasty (PTCA) relieves coronary obstruction through mechanical disruption of atherosclerotic lesions. It results in focal, traumatic injury, and loss of endothelial integrity, and is an intense stimulus for the formation of thrombus. Thrombus formation at the site of injury may result in reocclusion of the treated vessel and is thought to be a major factor contributing to the process of restenosis. Evidence from the cardiopulmonary bypass literature provides a strong argument that the intensity of anticoagulation influences the frequency with which thrombotic complications may develop. A growing body of evidence suggests that this is true for catheter-based intervention as well. As a result, patients are routinely anticoagulated with intravenous heparin during and immediately after angioplasty, and the degree or intensity of anticoagulation is frequently monitored during PTCA. This chapter presents current views on monitoring the efficacy and adequacy of anticoagulation for catheter-based interventional procedures.

Keywords

Intracoronary Thrombus Sheath Removal Anticoagulation Monitoring Abrupt Closure Abrupt Vessel Closure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mabin TA, Holmes DR Jr, Smith HC, et al. Intracoronary thrombus: Role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 3:198, 1985.Google Scholar
  2. 2.
    Ischinger T, Gruentzig AR, Meier B, Galan K. Coronary dissection and total coronary occlusion associated with percutaneous transluminal coronary angioplasty: Significance of initial angiographic morphology of coronary stenoses. Circulation 74:1371, 1986.PubMedGoogle Scholar
  3. 3.
    Laskey MAL, Deutsch E, Hirshfeld JW, Kussmaul WG, Barnathan E, Laskey WK. Influence of heparin therapy on percucaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus. Am J Cardiol 65:179, 1990.PubMedCrossRefGoogle Scholar
  4. 4.
    Sugrue DD, Holmes DR Jr, Smith HC, et al. Coronary artery thrombus as a risk factor for acute vessel occlusion during percutaneous transluminal coronary angioplasty: Improving results. Br Heart J 56:62, 1986.PubMedCrossRefGoogle Scholar
  5. 5.
    Deligonul U, Gabliani GI, Caralis DG, Kern MJ, Vandormael MG. Percutaneous transluminal coronary angioplasty in patients with intracoronary thrombus. Am J Cardiol 62:474, 1988.PubMedCrossRefGoogle Scholar
  6. 6.
    Lincoff A, Popma J, Ellis S, Hacker J, Topol E. Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic and therapeutic profile. J Am Coll Cardiol 19:926, 1992.PubMedGoogle Scholar
  7. 7.
    de Feyter PJ, van den Brand M, Jaarman G, van Domburg R, Serruys PW, Suryapranata H. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: Frequency, prediction, clinical course, management, and follow-up. Circulation 83:927, 1991.PubMedGoogle Scholar
  8. 8.
    Ellis SG, Roubin GS, King SB III, Douglas JSJ, Weintraub WS, Thomas RG, et al. Angiographic and clinical predictors of acute closure after native vessel angioplasty. Circulation 77:372, 1988.PubMedGoogle Scholar
  9. 9.
    Reeder GS, Bryant SC, Suman VJ, Holmes DR Jr. Intracoronary thrombus: Still a risk factor for PTCA Failure? Cathet Cardiovasc Diagn 34:191, 1995.PubMedCrossRefGoogle Scholar
  10. 10.
    Tan K, Sulke N, Taub N, Sowton E. Clinical and lesion morphologic determinants of coronary angioplasty success and complications: current experience. J Am Coll Cardiol 25:855, 1995.PubMedCrossRefGoogle Scholar
  11. 11.
    Hillegass WB, Ohman EM, O’Hanesian MA, Harrington RA, Faxon DP, Fortin DF, Ellis SG, Stack RS, Holmes DR, Califf RM. The effect of preprocedural intracoronary thrombus on patient outcome after percutaneous coronary intervention. J Am Coll Cardiol 25:94A, 1995.CrossRefGoogle Scholar
  12. 12.
    Ferguson JJ, Barasch E, Wilson JM, Strony J, Wolfe MW, Schweiger MJ, Leya F, Bonan R, Isner JM, Roubin GS, Cannon AD, Cleman M, Cabin HS, Adelman B, Bittl JA, and the Heparin Registry Investigators. The relation of clinical outcome to dissection and thrombus formation during coronary angioplasty. J Invas Cardiol 7:2, 1995.Google Scholar
  13. 13.
    White CJ, Ramee SR, Collins TJ, Escobar AE, Karsan A, Shaw D, Jain SP, Bass TA, Heuser RR, Teirstein PS, Bonan R, Walter PD, Smalling RW. Coronary thrombi increase PTCA risk. Angioscopy as a clinical tool. Circulation 93:253, 1996.PubMedGoogle Scholar
  14. 14.
    Waxman S, Sassower MA, Mittleman MA, Zarich S, Miyamoto A, Manzo KS, Muller JE, Abela GS, Nesto RW. Angioscopic predictors of early adverse outcome after coronary angioplasty in patients with unstable angina and non-Q wave rnyocardial infarction. Circulation 93:2106, 1996.PubMedGoogle Scholar
  15. 15.
    Tabata H, Mizuno K, Arakawa K, Satomura K, Shibuya T, Kurita A, Nakamura H. Angioscopic identification of coronary thrombus in patients with postinfarction angina. J Am Coll Cardiol 25:1282, 1995.PubMedCrossRefGoogle Scholar
  16. 16.
    Violaris AG, Melkert R, Hermann JR, Serruys PW. Role of angiographically identifiable thrombus on long term luminal renarrowing after coronary angioplasty. Circulation 93:889, 1996.PubMedGoogle Scholar
  17. 17.
    Ambrose JA, Almeida OD, Sharma SK, Torre SR, Marmur JD, Israel DM, Ratner DE, Weiss MB, Hjeimdahl-Monsen CE, Myler RK, Moses J, Unterecker WJ, Grunwald AM, Garrett JS, Cowley MJ, Anwar A, Sobolski J. Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the thrombolysis and angioplasty in unstable angina (TAUSA) trial. Circulation 90:69, 1994.PubMedGoogle Scholar
  18. 18.
    Lukas MA, Deutsch E, Hirshfeld JW Jr, Kussmaul WG, Barnathan E, Laskey WK. Influence of heparin therapy on percutaneous transluminal angioplasty outcome in patients with coronary arterial thrombus. Am J Cardiol 65:179, 1990.CrossRefGoogle Scholar
  19. 19.
    Douglas JS, Lutz JF, Clements SD, Robinson PH, Roubin GS, Lembo NJ, King SB. Therapy of large intracoronary thrombi in candidates fot percutaneous transluminal angioplasty (abstract). J Am Coll Cardiol 11(Suppl. A);238A, 1988.Google Scholar
  20. 20.
    Pow TK, Varricchione TR, Jacobs ASK, Ruocco NA, Ryan TJ, Christelis EM, Faxon DP. Does pretreatment with heparin prevent abrupt closure following PTCA? J Am Coll Cardiol 11:238A, 1988.Google Scholar
  21. 21.
    Hollman J, Gruentzig AR, Douglas JS Jr, King SB III, Ischinger T, Meier B. Acute occlusion after percutaneous transluminal angioplasty-a new approach. Circulation 68:725, 1983.PubMedGoogle Scholar
  22. 22.
    Popma JJ, Coller BS, Ohman EM, Bittl JA, Weitz J, Kuntz RE, Leon MB. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 108:4865, 1995.Google Scholar
  23. 23.
    Hattersley PG. Activated coagulation time of whole blood. JAMA 196:436, 1966.PubMedCrossRefGoogle Scholar
  24. 24.
    Hill JD, Dontigny L, de Levai M, Mielke CH Jr. A simple method of heparin management during prolonged extracorporeal circulation. Ann Thorac Surg 17:129, 1974.PubMedCrossRefGoogle Scholar
  25. 25.
    Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation: 1. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 69:674, 1975.PubMedGoogle Scholar
  26. 26.
    Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation: II. The use ot a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 69:685, 1975.PubMedGoogle Scholar
  27. 27.
    Babka R, Colby C, El-Etr A, Pifarre R. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery. J Thorac Cardiovasc Surg 73:780, 1977.PubMedGoogle Scholar
  28. 28.
    Roth JA, Cukingnan RA, Scott CR. Use of activated coagulation time to monitor heparin during cardiac surgery. Ann Thorac Surg 28:69, 1979.PubMedCrossRefGoogle Scholar
  29. 29.
    Scott JA, Berenstein A, Blumenthal D. Use of the activated coagulation time as a measure ot anticoagulation during interventional procedures. Radiology 158:849, 1986.PubMedGoogle Scholar
  30. 30.
    Kopelman HA, Klein LW, Agarwal JB. Adequate heparinization during PTCA: Assessment using activated clotting time. J Am Coll Cardiol 11:237A, 1988.CrossRefGoogle Scholar
  31. 31.
    Ogilby JD, Kopelman HA, Klein LW, Agarwal JB. Adequate heparinization during PTCA: Assessment using activated clotting times. Cathet Cardiovasc Diagn 18:206, 1989.PubMedCrossRefGoogle Scholar
  32. 32.
    Rath B, Bennett DH. Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal angioplasty. Br Heart J 63:18, 1990.PubMedCrossRefGoogle Scholar
  33. 33.
    Dougherty KG, Gaos CM, Bush HS, Leachman DR, Ferguson JJ. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn 26:260, 1992.PubMedCrossRefGoogle Scholar
  34. 34.
    Grayburn PA, Willard JE, Brickner ME, Eichhorn EJ. In vivo thrombus formation on a guidewire during intravascular ultrasound imaging: Evidence for inadequate heparinization. Cathet Cardiovasc Diagn 23:141, 1991.PubMedCrossRefGoogle Scholar
  35. 35.
    Mooney MR, Mooney JF, Goldenberg IF, Almquist AK, Tassel RAV. Percutaneous Transluminal coronary angioplasty in the setting of large intracoronary thrombi. Am J Cardiol 65:427, 1990.PubMedCrossRefGoogle Scholar
  36. 36.
    Satler LF, Leon MB, Kent KM, Pichard AD. Strategies for acute occlusion after coronary angioplasty. J Am Coll Cardiol 19:936, 1992.PubMedGoogle Scholar
  37. 37.
    Ferguson JJ. All ACTs are not created equal. Tex Heart Inst J 19:1, 1992.PubMedGoogle Scholar
  38. 38.
    Avendano A, Ferguson JJ. Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal angioplasty. J Am Coll Cardiol 23:907, 1994.PubMedGoogle Scholar
  39. 39.
    Vaitkus PT, Hermann HC, Laskey WK. Management and immediate outcome of patients with intracoronary thrombus during percutaneous transluminal coronary angioplasty. Am Heart J 124:1, 1992.PubMedCrossRefGoogle Scholar
  40. 40.
    Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR. The relationship between procedural activated clotting times and in-hospital post-PTCA outcome. J Am Coll Cardiol 23:1061, 1994.PubMedGoogle Scholar
  41. 41.
    McGarry TF Jr, Gottlieb RS, Morganroth J, Zelenkofske SL, Kasparian H, Duca PR, Lester RM, Kreulen TH. The relationship of anticoagulation level and complications after successful percutaneous transluminal angioplasty. Am Heart J 123:1445, 1992.PubMedCrossRefGoogle Scholar
  42. 42.
    Frierson JH, Dimas AP, Simpfendorfer CC, Pearce G, Miller M, Franco I. Is aggressive heparinization necessary tor elective PTCA? Cathet Cardiovasc Diagn 28:279, 1993.PubMedCrossRefGoogle Scholar
  43. 43.
    Narins CR, Hillegass WB Jr, Nelson CL, Tcheng JE, Harrington RA, Phillips HR, Stack RS, Califf RM. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 93:667, 1996.PubMedGoogle Scholar
  44. 44.
    Blumenthal RS, Carter AJ, Resar JR, Coombs V, Gloth ST, Dalai J, Brinker JA. Comparison of bedside and hospital laboratory coagulation studies during and after coronary intervention. Cathet Cardiovasc Diagn 35:9, 1995.PubMedCrossRefGoogle Scholar
  45. 45.
    Perin EC, Turner SA, Ferguson JJ. Relationship between the response to heparin and restenosis following PTCA. Circulation 82(Suppl. III):497, 1990.Google Scholar
  46. 46.
    Lins M, Zurborn KH, Dau O, Muurling S, Herrmann G, Simon R. Does coagulation activation cause restenosis in patients undergoing directional coronary atherectomy? (abstr) J Am Coll Cardiol 27(Suppl. A):391, 1996.CrossRefGoogle Scholar
  47. 47.
    Koch KT, Piek JJ, Mulder K, Peters RJG, David GK. Safety of low-dose heparin in elective percutaneous transluminal coronary angioplasty. Eur Heart J l6(Suppl.):85, 1995.Google Scholar
  48. 48.
    Boccara A, Benamer H, Juliard JM, Aubry P, Goy P, Himbert D, Karnillon GJ, Steg PG. A radomized trial of a fixed high dose versus a weight-adjusted low dose of intravenous heparin during coronary angioplasty. Circulation, in press.Google Scholar
  49. 49.
    Lincoff AM, Tcheng JE, Bass TA, Popma JJ, Teirstein PS, Kleiman NS, Weisman HF, Musco MH, Cabot CF, Berdan LG, Califf RM, Topol EJ, PROLOG Investigators. A multicenter, randomized, double-blind pilot trial of standard versus low dose weight-adjusted heparin in patients treated with the platelet GP IIb/IIIa receptor antibody c7E3 during percutaneous coronary revascularization. J Am Coll Cardiol 25:80A, 1995.CrossRefGoogle Scholar
  50. 51.
    Ferguson JJ. EPILOG and CAPTURE trials halted because of positive interim results. Circulation 93:637, 1996.PubMedGoogle Scholar
  51. 52.
    Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, de Bonon D, Ferguson J, Willerson JT, Strony J, Ganz P, Cohen MD, Raymond R, Fox I, Maraganore J, Adelman B. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 87:1622, 1993.PubMedGoogle Scholar
  52. 53.
    Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B, for the Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 333:764, 1995.PubMedCrossRefGoogle Scholar
  53. 54.
    Wilson JM, Khoshnevis R, Le D, Ferguson JJ, Yaryura RA, Reddy KJ, Waly HM. Are weight-based heparin boluses more predictable? J Invas Cardiol 8:66, 1996.Google Scholar
  54. 55.
    Snitzer R, Miremath YJ, Lee J, Lasala JM, Eisenberg PR, Winters KJ. Suppression of intracoronary thrombin activity by weight-adjusted heparin administration during coronary interventions. Circulation 92(Suppl. I):I609, 1995.Google Scholar
  55. 56.
    Winters KJ, Oltrona L, Hiremath YJ, Lasala JM, Eisenberg PR. Heparin-resistant thrombin activity is associated with acute ischemic events during high-risk coronary interventions. Circulation 92(Suppl. I):I608, 1995.Google Scholar
  56. 57.
    Hirshfeld JW, Goldberg S, MacDonald R, Vetrovec G, Bass T, Taussig A, Margolis J, Jugo R, Pepine C. Lesion and procedure-related variables predictive of restenosis after PTCA — A report from the MHEART study. Circulation 76:IV215, 1987.Google Scholar
  57. 58.
    Saenz CB, Baxley WA, Bulle TM, Cherre JM, Dean LS. Early and late effect of heparin infusion following elective angioplasty. Circulation 78:1198, 1988.Google Scholar
  58. 59.
    Ellis SG, Roubin GS, Wilentz J, Douglas JS, King SB. Effect of 18-to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 117:777, 1989.PubMedCrossRefGoogle Scholar
  59. 60.
    Walford CD, Midei MM, Aversano TR, Gottlieb SO, Chew PH, Siu CO, Brin KP, Brinker JA. Heparin after PTCA: Increased early complications and no clinical benefit. Circulation 84:11592, 1991.Google Scholar
  60. 61.
    Tanjura L, Pinto I, Centemero M, Chaves A, Mattos L, Feres F, Maldonado G, Cano H, Sousa A, Sousa JE. Use of heparin in coronary angioplasty: Randomized trial for prevention of abrupt closure. Eur Heart J 14:179, 1993.Google Scholar
  61. 62.
    Friedman HZ, Cragg DR, Glazier SM, Gangadharan V, Marsalese DL, Schreiber TL, O’Neill WW. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary. J Am Coll Cardiol 24:1214, 1994.PubMedGoogle Scholar
  62. 63.
    Pizzuli L, Zirbes M, Fehske W, Pfeiffer D. Omission of intravenous heparin and nitroglycerin following uncomplicated coronary angioplasty: A prospective. Circulation 92:174, 1995.Google Scholar
  63. 64.
    Pitney MR, Kelly SA, Allan RM, Giles RW, McCredie M, Walsh WF. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty. Cathet Cardiovasc Diagn 37:145, 1996.PubMedCrossRefGoogle Scholar
  64. 65.
    Ferguson JJ, Dohmen P, Wilson JM, Vaughn WK, Khoshnevis R, Kmonicek P, McKinney AA, Plachetka JR. Results of a national survey on anticoagulation for PTCA. J Invas Cardiol 7:136, 1995.Google Scholar
  65. 66.
    Rund MM, Smith DD, DeLuca SA, Rouse CL, Sigmon KN, Juran NB, O’Brien M, Tcheng JE for the IMPACT II Study Coordinators/Investigators. Heparin during coronary angioplasty: Are there any rules? Circulation 90:1487, 1994.Google Scholar
  66. 67.
    Kaiser B. Anticoagulant and antithrombotic actions of recombinant hirudin. Semin Thromb Hemost 17:130, 1991.PubMedCrossRefGoogle Scholar
  67. 68.
    van den Bos AA, Deckers JW, Heyndrickx GR, et al. PTCA with hirudin is associated with less acute cardiac complications than with heparin (abstr). Circulation 86(Suppl. I):I372, 1992.Google Scholar
  68. 69.
    Sarembock IT, Gertz SD, GimpJe LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 84:232, 1991.PubMedGoogle Scholar
  69. 71.
    Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI)9A trial. Circulation 90:1624, 1994.PubMedGoogle Scholar
  70. 72.
    Neuhaus K-L, v. Essen R, Tebbe U, Jessel A, Heinrichs H, Mäurer W, Döring W, Harmjanz D, Kötter V, Kaihammer E, Simon H, Horacek T. Safety observations from the pilot phase of the radomized r-hirudin for improvement of thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 90:1638, 1994.PubMedGoogle Scholar
  71. 73.
    Serruys PW, Herrman J-PR, Simon R, Rutsch W, Bode C, Laarman G-J, van Dijk R, van den Bos AA, Umans VAWM, Fox KAA, Close P, Deckers JW, for the Helvetica Investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 333:757, 1995.PubMedCrossRefGoogle Scholar
  72. 74.
    Ahmed WH, Meckel CR, Grines CL, Strony J, Borzak S, Kraft PL, Timmis GC, Ferguson JJ, Adelman B, Bittl JA, on behalf of the Hirulog Angioplasty Study Investigators. Relation between ischemic complications and activated clotting times during coronary angioplasty: Different profiles for heparin and hirulog. Circulation 92(Suppl. I):I608, 1995.Google Scholar
  73. 75.
    Hursting MJ, Joffrion JL, Brooks RL, Swan SK. A comparison of the pharmacodynamics of heparin and argatroban (a direct thrombin inhibitor) in healthy volunteers (abstr). American Society of Hematology, 1996.Google Scholar
  74. 76.
    Carteaux JP, Gast A, Tschopp TB, Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 91:1568, 1995.PubMedGoogle Scholar
  75. 77.
    Hursting MJ, Joffrion JL, Brooks RL, Swan SK, Ferguson JJ. Differential effects of Argatroban (a direct thrombin inhibitor) and heparin on the HemoTec and Hemochron activated clotting times (abstr). American Society of Hematology, 1996.Google Scholar
  76. 78.
    The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasry. N Engl J Med 330:956, 1994.CrossRefGoogle Scholar
  77. 79.
    Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley Seth, Ivanhoe R, George BS, Fincel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of The EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet Ilb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 343:881, 1994.PubMedCrossRefGoogle Scholar
  78. 80.
    Lincoff AM, Tcheng JE, Califf RM, Bass T, Popma JJ, Teirstein PS, Kleiman NS, Hattel LS, Anderson HV, Ferguson JJ, Cabot CF, Anderson KM, Berdan LG, Musco MH, Weisman HF, Topol EJ, for the PROLOG Investigators. A multicenter, randomized, double-blind pilot trial of standard versus low dose weight-adjusted heparin in patients treated with the platelet GP Ilb/IIIa receptor antibody fragment c7E3 Fab (Abciximab) during perecutaneous coronary revascularization. Am J Cardiol 79:286, 1997.PubMedCrossRefGoogle Scholar
  79. 81.
    The EPILOG Investigators: Platelet glycoprotein IIb/ IIIa receptor blockade and low-dose heparin during percutaneous coronary intervention. N Engl J Med 336:1689, 1997.CrossRefGoogle Scholar
  80. 82.
    The CAPTURE Investigators: Randomized placebocontrolled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study Lancet 349:1429, 1997.CrossRefGoogle Scholar
  81. 83.
    Ferguson JJ. Meeting Highlights: American College of Cardiology 45th Annual Scientific Session, Orlando, Florida, March 24 to 27, 1996. Circulation 94:1, 1996.PubMedGoogle Scholar
  82. 84.
    Aguirre FV, Ferguson JJ, Blankenship JC, Pieper KS, Taylor M, Harrington RA, Rund M, Caracciolo EA, Donohue TJ, Califf RM, Lincoff AM, Tcheng JE, Topol EJ, for the IMPACT-II Investigators. Association of pre-intervention activated clotting times (ACT) and clinical outcomes following percutaneous coronary revascularization: Results from the IMPACT-II trial. J Am Coll Cardiol 27(Suppl. A):83A, 1996.CrossRefGoogle Scholar
  83. 85.
    Mascelli MA, Lance E, Mack S, Weisman H, Schaible T, Jordan R. Rapid assessment of platelet inhibition using a modified whole blood aggregometer (Aggrestat™) in PTCA patients receiving ReoPro. J Am Coll Cardiol 27(Suppl. A):361A, 1996.CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • James J. Ferguson
  • James M. Wilson

There are no affiliations available

Personalised recommendations